Regenosine

Regenosine is a privately held biotechnology startup founded in 2018, with a vision to revolutionize the treatment of osteoarthritis by leveraging the healing potential of adenosine for tissue regeneration. Their proprietary platform technology focuses on developing and marketing first-in-class regenerative therapies, with a lead product aimed at regenerating cartilage in joints affected by osteoarthritis. Their innovative approach targets the rapidly growing joint preservation market, offering a disease-modifying therapy with uncompromising efficacy relative to existing technologies. This breakthrough has the potential to significantly improve clinical outcomes, enhance patient quality of life, and reduce the overall healthcare costs associated with regenerative medicine. Their most recent investment of $25.00K came in the form of a grant from NJEDA on 16 February 2023. Regenosine operates from the United States, and their emphasis on pioneering regenerative therapies positions them as a promising player within the biotechnology, healthcare, and pharmaceutical industries.